|Articles|October 1, 2000

Antibody-Targeted Chemotherapy for the Treatment of Relapsed Acute Myeloid Leukemia
Volume 6
Issue 18 Suppl

Antibody-Targeted Chemotherapy for the Treatment of Relapsed Acute Myeloid Leukemia

Author(s)John P. Williams, MD, MBA, Heather L. Handler, MPH, MBA

Download PDF: Antibody-Targeted Chemotherapy for the Treatment of Relapsed Acute Myeloid Leukemia

Articles in this issue

over 25 years ago

Article

Commentary: New Research and Treatment Options for Acute Myeloid Leukemia

over 25 years ago

Article

Continuing Medical Education Quiz

over 25 years ago

Article

Overview: Treatment of Acute Myeloid Leukemia

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!

Related Content

The Health Information Technology Special Issue: Tracking Expansion Across Settings, Technologies, and Stakeholders

ByNate C. Apathy, PhD

January 27th 2026

Building Trust: Public Priorities for Health Care AI Labeling

ByMorgan L. Sielaff, BS,Jodyn Platt, PhD, MPH,Sean Tan, MPP,Kerry A. Ryan, MA,Paige Nong, PhD,Sharon L. R. Kardia, PhD

January 27th 2026

Ambient AI Tool Adoption in US Hospitals and Associated Factors

ByFreddie Yang, MA,Ilana Graetz, PhD

January 27th 2026

Motivating and Enabling Factors Supporting Targeted Improvements to Hospital-SNF Transitions

ByTaylor I. Bucy, PhD,John P. McHugh, PhD,Dori A. Cross, PhD

January 26th 2026

Specialty and Operator Status Influence Electronic Health Record Use Variation

ByPhillip D. Jenkins, MD,Gary Grunkemeier, PhD,Elizabeth Weirich, DO,An Dinh, MS,Ruchi Thanawala, MD, MS,Jeffrey A. Gold, MD,Julie Doberne, MD, PhD

January 22nd 2026

Latest CME

Online Article

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

2.0 Credits / General Pharmacy

Antibody-Targeted Chemotherapy for the Treatment of Relapsed Acute Myeloid Leukemia

Articles in this issue

Newsletter

Related Content

The Health Information Technology Special Issue: Tracking Expansion Across Settings, Technologies, and Stakeholders

Building Trust: Public Priorities for Health Care AI Labeling

Ambient AI Tool Adoption in US Hospitals and Associated Factors

Motivating and Enabling Factors Supporting Targeted Improvements to Hospital-SNF Transitions

Specialty and Operator Status Influence Electronic Health Record Use Variation

Latest CME

Innovations in Medicine: 2024 Lineup of New and Approved Specialty Drugs

Trending on AJMC

AAP Breaks With CDC, Maintains Broader 2026 Childhood and Adolescent Vaccine Schedule

New Dermatologic Therapies Make Waves at Maui Derm 2026

Experts Warn CDC Childhood Immunization Schedule Revisions Could Reduce Uptake, Erode Public Trust

Trulicity, Botox Headline Drugs Included in the Third Cycle of Medicare Price Negotiations

FDA Greenlights D-VRd Quadruplet for Newly Diagnosed Multiple Myeloma